FindTrial
Sign In

GLP-1 infusion

OTHER5 trials

Sponsors

University of Rome Tor Vergata, University Hospital, Gentofte, Copenhagen, Papworth Hospital NHS Foundation Trust, David D'Alessio, M.D.

Conditions

Glucose IntoleranceHyperglucagonemiaHyperglycemiaIncretin ActionInsulin SecretionMetabolic SyndromeObesityRight Coronary Artery Percutaneous Coronary Intervention

Phase 1

Incretin Action in Physiology and Diabetes
CompletedNCT02550548
David D'Alessio, M.D.Insulin Secretion
Start: 2016-04-21End: 2021-04-16Updated: 2023-11-18

Unknown Phase

Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome
CompletedNCT00856700
University of Rome Tor VergataMetabolic Syndrome
Start: 2008-11-30End: 2012-06-30Updated: 2013-12-11
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
CompletedNCT00862589
University Hospital, Gentofte, CopenhagenGlucose Intolerance, Hyperglucagonemia, Hyperglycemia
Start: 2006-10-31End: 2007-03-31Updated: 2009-03-18
Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.
CompletedNCT01232244
University Hospital, Gentofte, CopenhagenIncretin Action, Obesity
Start: 2010-10-31End: 2012-01-31Updated: 2013-12-10
Diastolic RV EvAluation With Millar Catheter to Investigate the Effect of Glucagon-Like Peptide-1 (GLP-1) on Right Ventricular Function During Elective Coronary Angioplasty and Stenting
NCT02236299
Papworth Hospital NHS Foundation TrustRight Coronary Artery Percutaneous Coronary Intervention, Right Ventricular Diastolic Dysfunction
Start: 2014-09-30Target: 30Updated: 2016-04-11